Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 9.34B +144.4% |
| Revenue (ttm) | 281.99M +34.8% |
| Net Income | 82.91M +59.3% |
| EPS | 1.22 +51.8% |
| Shares Out | 64.71M |
| PE Ratio | 118.19 |
| Forward PE | 57.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 501,194 |
| Open | 147.73 |
| Previous Close | 149.50 |
| Day's Range | 142.43 - 147.95 |
| 52-Week Range | 54.50 - 160.81 |
| Beta | 1.79 |
| Analysts | Strong Buy |
| Price Target | 170.38 (+18.05%) |
| Earnings Date | Aug 5, 2026 |
About PTGX
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class or... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price target is $170.38, which is an increase of 18.05% from the latest price.
News
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control...
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in ac...
Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital
BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $178 from $112 and keeps an Outperform rating on the shares. The firm notes that the Icotyde initial…
Protagonist Therapeutics price target raised to $170 from $145 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $170 from $145 and keeps a Buy rating on the shares as part of a broader…
Protagonist Therapeutics price target raised to $173 from $118 at Wedbush
Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $173 from $118 and keeps an Outperform rating on the shares. The firm cites last week’s Q2 update, based…
Protagonist Therapeutics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Richard Law upgraded Protagonist Therapeutics (PTGX) to Buy from Neutral with a price target of $186, up from $110, following the Q2 report. Given the favorable Phase…
Protagonist Therapeutics price target raised to $175 from $130 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Protagonist Therapeutics (PTGX) to $175 from $130 and keeps a Buy rating on the shares post the Q2 report. The…
Protagonist Therapeutics price target raised to $173 from $116 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $173 from $116 and keeps a Buy rating on the shares post the Q2 report.
Protagonist Therapeutics price target raised to $153 from $151 at Barclays
Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $153 from $151 and keeps an Overweight rating on the shares.
Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93
Reports Q2 revenue $213.48M, consensus $223.17M. “The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch of ICOTYDE through our strategic partner...
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026 Comprehensive Phase 2b Program with PN-...
Protagonist Therapeutics Quarterly report: Q2 2026
Protagonist Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Protagonist Therapeutics Earnings release: Q2 2026
Protagonist Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Protagonist Therapeutics Slides: Corporate presentation
Protagonist Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Protagonist Therapeutics price target raised to $165 from $137 at Citizens
Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $165 from $137 and keeps an Outperform rating on the shares ahead of the Q2 report on August 5.
Protagonist Therapeutics price target raised to $151 from $119 at Barclays
Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $151 from $119 and keeps an Overweight rating on the shares. The firm adjusted the price target as part…
Protagonist Therapeutics price target raised to $145 from $121 at Truist
Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $145 from $121 and keeps a Buy rating on the shares. The firm remains bullish on the broader Icotyde…
Protagonist Therapeutics Transcript: AGM 2026
The meeting covered board introductions, four key proposals, and voting procedures. All proposals—including director elections, executive compensation, auditor ratification, and the equity incentive plan—were approved. Voting results will be filed with the SEC.
Protagonist Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing as a commercial-stage biotech with strong financials, highlighted by Icotyde's successful launch and anticipated Rusfertide approval. Its robust, de-risked pipeline includes innovative oral peptides for I&I and obesity, with strategic partnerships and shareholder rewards planned.
Protagonist Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Strong royalty streams from major partnerships and a robust, de-risked pipeline support self-funded R&D and potential share buybacks. ICOTYDE is positioned for major growth, while rusfertide's opt-out deal secures significant payments and high royalties. Multiple innovative programs advance toward key milestones.
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will...
Protagonist Therapeutics Slides: Company presentation
Protagonist Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics price target raised to $130 from $125 at Citi
Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $130 from $125 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics (PTGX) to $137 from $120 and keeps an Outperform rating on the shares. Protagonist Therapeutics is expecte...